Pierre Fabre Laboratories and RedRidge Bio Enter R&D Collaboration & License Agreement for Biparatopic Antibody (BPA) Candidates
Shots:
- Pierre Fabre has partnered with RedRidge for BPA drugs against various targets in oncology, dermatology & rare diseases, where the latter will engineer, screen, & characterize BPAs for jointly selected targets, while Pierre will advance 2 co-development programs
- As per the deal, RedRidge will hold marketing rights in the US, Canada, & Japan for the 2 programs, while Pierre will gain rest-of-world rights as well as exclusive global rights for a 3rd program after preclinical stage
- Financial terms remain undisclosed but incl. an upfront, milestones, royalties, Series A investment, & research funding from Pierre to RedRidge. R&D costs for co-development programs will be shared
Ref: PRNewsWire | Image: Pierre Fabre Laboratories & RedRidge Bio
Related News:- Pierre Fabre Laboratories Reports the EC’s Approval of Braftovi Plus Mektovi to Treat Advanced Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
